On the stock market since 1994, it operates in the world of health and science. It has 61 employees. Now — the numbers.
This is an established company with proven profits.
That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.
Average growth of 96% a year over the last 4 years. Red columns mark years that ended in a loss.
If every debt were paid off today, $44.0M would still be left in the vault — a solid cushion for hard times.
Executives buying with their own money is usually read as confidence in the company’s future.
The stock trades 18% below its peak. The market has trimmed its expectations for the company.
The net profit margin is 26% — still a thick cushion, though costs have been eating into it lately.
Over the last 3 years, sales grew about 96% a year on average.
There is $46.7M in the vault; even if every debt were paid off, $44.0M would remain.
This stock swings about 2.4 times as much as the market average. Big rallies — and big drops — can both happen fast.
Since the drop from its peak, buyer appetite hasn’t come back.
On our five-subject report card, LJPC sits in the middle of the class: some subjects shine, others don’t. The grade moves as the numbers move.
The takeaway: LJPC is an established business that has proven its profits for years. The real debate isn’t the quality of the business — it’s whether the price paid for the stock is too high.